Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

16S rRNA gene sequencing on a benchtop sequencer: accuracy for identification of clinically important bacteria.

Watts GS, Youens-Clark K, Slepian MJ, Wolk DM, Oshiro MM, Metzger GS, Dhingra D, Cranmer LD, Hurwitz BL.

J Appl Microbiol. 2017 Dec;123(6):1584-1596. doi: 10.1111/jam.13590. Epub 2017 Nov 7.

2.

Agglomerative epigenetic aberrations are a common event in human breast cancer.

Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW.

Cancer Res. 2008 Oct 15;68(20):8616-25. doi: 10.1158/0008-5472.CAN-08-1419.

3.
4.

Epigenetic inactivation of the HOXA gene cluster in breast cancer.

Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS, Klimecki WT, Kim C, Futscher BW.

Cancer Res. 2006 Nov 15;66(22):10664-70. Epub 2006 Nov 6.

5.

AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells.

Li H, Watts GS, Oshiro MM, Futscher BW, Domann FE.

Oncogene. 2006 Aug 31;25(39):5405-15. Epub 2006 Apr 24.

PMID:
16636674
6.

Epigenetic regulation of the cell type-specific gene 14-3-3sigma.

Oshiro MM, Futscher BW, Lisberg A, Wozniak RJ, Klimecki WT, Domann FE, Cress AE.

Neoplasia. 2005 Sep;7(9):799-808.

7.

Epigenetic silencing of DSC3 is a common event in human breast cancer.

Oshiro MM, Kim CJ, Wozniak RJ, Junk DJ, Muñoz-Rodríguez JL, Burr JA, Fitzgerald M, Pawar SC, Cress AE, Domann FE, Futscher BW.

Breast Cancer Res. 2005;7(5):R669-80. Epub 2005 Jun 16.

8.

Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.

Nouzova M, Holtan N, Oshiro MM, Isett RB, Munoz-Rodriguez JL, List AF, Narro ML, Miller SJ, Merchant NC, Futscher BW.

J Pharmacol Exp Ther. 2004 Dec;311(3):968-81. Epub 2004 Aug 9.

PMID:
15302897
9.

The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.

Watts GS, Oshiro MM, Junk DJ, Wozniak RJ, Watterson S, Domann FE, Futscher BW.

Neoplasia. 2004 May-Jun;6(3):187-94.

10.

Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression.

Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, Futscher BW.

Oncogene. 2003 Jun 5;22(23):3624-34.

PMID:
12789271
11.

The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.

Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS.

Leukemia. 2003 Feb;17(2):451-7.

PMID:
12592346
12.

Role for DNA methylation in the control of cell type specific maspin expression.

Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, Domann FE.

Nat Genet. 2002 Jun;31(2):175-9. Epub 2002 May 20.

PMID:
12021783
13.

Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.

Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS.

Clin Cancer Res. 2001 Dec;7(12):4262-71.

14.

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.

Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH.

Blood. 2001 Aug 1;98(3):805-13.

15.

Dolasetron-associated venous irritation.

Oshiro MM.

Am J Health Syst Pharm. 2000 Aug 15;57(16):1533-4. No abstract available.

PMID:
10965398
16.
17.

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R.

Immunity. 1999 Jan;10(1):105-15.

18.

Androgenic expression in the submandibular gland of zinc-deficient mice.

Minetti CA, Oshiro MM, Santos MF, Romaldini JH, Moura NM, Valle LB, Oliveira-Filho RM.

Ann Nutr Metab. 1992;36(3):167-74.

PMID:
1530286

Supplemental Content

Loading ...
Support Center